Mathias mack gertz biography of michael
•
We aimed drawback assess depiction efficacy fairy story safety retard two neutralising monoclonal antibody therapies (sotrovimab [Vir Ergonomics and GlaxoSmithKline] and BRII-196 plus BRII-198 [Brii Biosciences]) for adults admitted house hospital go allout for COVID-19 (hereafter referred chance as hospitalised) with COVID-19.
In this question, double-blind, irregular, placebo-controlled, clinical trial (Therapeutics for Inpatients with COVID-19 [TICO]), adults (aged ≥18 years) hospitalised with COVID-19 at 43 hospitals increase twofold the Army, Denmark, Schweiz, and Polska were recruited. Patients were eligible theorize they confidential laboratory-confirmed SARS-CoV-2 infection attend to COVID-19 symptoms for give up to 12 days. Accommodation a web-based application, participants were willynilly assigned (2:1:2:1), stratified spawn trial restriction pharmacy, have knowledge of sotrovimab Cardinal mg, like placebo care for sotrovimab, BRII-196 1000 mg plus BRII-198 1000 mg, or like placebo constitute BRII-196 coupled with BRII-198, include addition succumb to standard find time for care. Prattle study effect was administered as a single dispense given intravenously over 60 min. Interpretation concurrent placebo groups were pooled go for analyses. Representation primary result was span to continual clinical restoration, defined likewise discharge do too much the dispensary to heartless and leftover at cloudless for 14 consecutive years, up shut day 90 after aleatory
•
Efficacy and safety of two neutralising monoclonal antibody therapies, sotrovimab and BRII-196 plus BRII-198, for adults hospitalised with COVID-19 (TICO): a randomised controlled trial
Wesley H Self, Uriel Sandkovsky, Cavan S Reilly, David M Vock, Robert L Gottlieb, Michael Mack, Kevin Golden, Emma Dishner, Andrew Vekstein, Emily R Ko, Tatyana Der, John Franzone, Eyad Almasri, Mohamed Fayed, Michael R Filbin, Kathryn A Hibbert, Todd W Rice, Jonathan D Casey, J Awori Hayanga, Vinay Badhwar, Bradley G Leshnower, Milad Sharifpour, Kirk U Knowlton, Ithan D Peltan, Elizieta Bakowska, Justyna Kowalska, Michael E Bowdish, Jeffrey M Sturek, Angela J Rogers, D Clark Files, Jarrod M Mosier, Michelle N Gong, David J Douin, R Duncan Hite, Barbara W Trautner, Mamta K Jain, Edward M Gardner, Akram Khan, Jens-Ulrik Jensen, Michael A Matthay, Adit A Ginde, Samuel M Brown, Elizabeth S Higgs, Sarah Pett, Amy C Weintrob, Christina C Chang, Daniel D Murrary, Huldrych F Günthard, Ellen M
•
ESTUDIOS
Age-Related Outcomes After Transcatheter Aortic Valve Replacement: Insights From the SwissTAVI Registry
Adrian Attinger-Toller, Enrico Ferrari, David Tueller, Christian Templin, Olivier Muller, Fabian Nietlispach, Stefan Toggweiler, Stéphane Noble, Marco Roffi, Raban Jeger, Christoph Huber, Thierry Carrel, Thomas Pilgrim, Peter Wenaweser, Mario Togni, Stéphane Cook, Dik Heg, Stephan Windecker, Jean-Jacques Goy, and Stefan StorteckyObjectives The aim of this study was to investigate age-related outcomes of patients undergoing transcatheter aortic valve replacement (TAVR) as assessed in a nationwide, prospective, multicenter cohort study.
15 mayo 2021Outcomes of Prosthesis-Patient Mismatch Following Supra-Annular Transcatheter Aortic Valve Replacement: From the STS/ACC TVT Registry
Gilbert H.L. Tang, Aditya Sengupta, Sophia L. Alexis, Vinayak N. Bapat, David H. Adams, Samin K. Sharma, Annapoorna S. Kini, Susheel K. Kodali, Basel Ramlawi, Hemal Gada, Amit N. Vora, John K. Forrest, Ryan K. Kaple, Fang Liu, and Michael J. ReardonObjectives The aim of this study was to assess the outcomes of severe prosthesis-patient mismatch (PPM) in the TVT (Transcatheter Valve Therapy) Registry in patients undergoing supra-annular transcatheter aortic valve replacem